BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
4 DSLR Cameras for Amateurs in 2024 - 2Excursion to Different Universes: the Top Sci-fi Motion pictures Ever
- 3Creativity Revealed: A Survey of \Making Shocking Looks\ Cosmetics Item
- 4Full SNAP benefits must be paid ‘promptly,’ USDA tells states as government reopens
- 5Which Startup's Innovation Could Reform Medical care?
- Brazil's agricultural research agency gets cannabis research greenlight
- Public Parks in the USA
- 6 Asian Urban areas to Visit
- Independence from the rat race: How to Save and Contribute Carefully
- Forget Doctor Strange. Benedict Cumberbatch’s newest role may be his most haunting.
- The most effective method to Pick the Best Wellbeing Highlights for Seniors in SUVs
- Most loved Road Food: Which One Prevails upon You?
- Instructions to Arrange Your Compensation During Medical caretaker Prospective employee meetings
- The Job of a Land Legal counselor in Property Exchanges
